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Bone: biomechanic and endocrine function
Bones are part of the skeleton. They are distinguished by their den-sity, hardness, and strength and are able to resist different mechan-
ical forces, loads and stresses, such as compression, tension, bending, 
shearing or torsion. The primary functions of bones are mechanical 
support of the organism in resisting gravitational forces, enabling loco-
motion, mineral homeostasis, hematopoiesis, and the protection of in-
ternal organs. Bones can also be considered an endocrine organ. 
The biomechanics of bone and bones is a science that uses the laws 
and methods of theoretical and applied technical physics and mechan-
ics to solve biological and medical problems, researching mechanical 
characteristics of the biological organisms, systems, organs, or tissues 
and kinematics or kinetics, and moving of whole organism applying 
statics – a science of equilibrium of forces, and kinetics and kinematics, 
sciences of body movement. We can conclude that biomechanics is a 
multidisciplinary, interdisciplinary synthetic and multi-level science.
Bones were the most well-known morphological parts of the organ-
ism throughout the prehistory and history of the humanity. After pu-
trefaction and decomposition of soft tissues, bones rested for thousands 
of years intact for macroscopic and microscopic investigation of mor-
phology and strength. They are the only parts of organism believed to 
be without secrets. Through prehistory Man has known about animal 
and human skeletal morphology. Bones were even used as tools or weap-
ons. Paleontology and anthropology could, through osteological tests, 
follow the evolution of many organisms, including human, and their 
physiology and pathology.
Life on the planet earth evolved inside the planet’s gravitational field. 
This fact influenced ontogenesis and phylogenesis and the growth and 
the way of life of all living organisms. Today’s current problems are 
investigations of living conditions with diminished or increased gravi-
tational force in connection with space and other civil and military re-
search programs.
Living organisms change through the time in almost all aspects: 
dimensions, volume, weight, structure, mass distribution, energy equi-
librium, mobility of joints, and the mobility of the entire organism, or 
only its parts. Because of this fact, biomechanics is more complicated 
than its components: technical, biological or medical sciences. Biome-
chanics has overlapped many medical and clinical sciences (Figure 1), 
and also impinged on many other related professional branches (Figure 
2). Now, when in scientific sphere, the decade, dedicated to investigation 
of bone and bones is finished, many secrets of bone now are well known, 
but not all. Living and dead bone materials are essentially different. How 
other supporting tissues, bone tissue consists bone cells and intercellular 
material. Osteoblasts, osteoclasts and osteocytes are cells enabling com-
plicated bone metabolism, microscopic structure of bone, bone con-
VASILIJE NIKOLIĆ1
DRAŠKO PAVLOVIĆ2
1 Retired professor of anatomy, Faculty of Medicine, 
University of Zagreb
2 Department of Nephrology and Dialysis, Sestre 
Milosrdnice University Hospital, Zagreb, Croatia
Correspondence: 
Prof.dr.sc. Vasilije Nikoli} 
Palmoti}eva 23, 10000 Zagreb 
E mail: vnikolic@mefos.hr
 
Received February 15, 2015.
V. Nikolić and D. Pavlović Bone: biomechanic and endocrine functione
2 Period biol, Vol 117, No 1, 2015.
struction, functional mechanical adaptation, electrical 
phenomena and aging effects. The family of bone cells 
include active osteoblasts, secreting intercellular organic 
matrix, inactive lining bone cells enveloping the endos-
teal surface of bone and the walls of the Harversian ca-
nals, osteocytes are converting from osteoblasts and are 
inserted in lacunae, multi-nuclear osteoclasts are differ-
entiated from precursor cells and they dissolve and resorb 
bone (1-7).
Bone as Endocrine Organ
Bone has been traditionally viewed as a very dynamic 
organ. There is constant bone formation and bone resorp-
tion. Classically, bone function has been considered a 
mechanical one, i.e. the support and locomotion of the 
organism. Bone was also recognized as a target organ for 
several hormones, mainly parathyroid hormone, sex hor-
mones and 1,25(OH)2 D vitamin (8). On the other hand, 
recent advances in the field of bone biology show that one 
type of bone cell, osteocytes, secrete a specific protein, 
sclerostin, which could act on other types of cells, osteo-
blasts, in paracrine fashion (9). Moreover, in the last few 
years, bone has been identified as a typical endocrine or-
gan because of its capacity to secrete hormones in circula-
tion. One hormone, osteocalcin, is involved in glucose 
and energy metabolism and another, fibroblast growth 
factor 23 (FGF 23), is involved in mineral homeostasis, 
or better to say phosphate metabolism (10). There also 
some other factors, e.g. sclerostin. It is a glycoprotein pro-
duced by osteocytes that inhibits bone formation (11). 
Bone morphogenetic proteins, besides bone formation 
properties, play a role in several clinical disorders, from, 
vascular calcification to obesity and diabetes (12).
Osteocalcin
Osteocalcin is a bone matrix protein produced by os-
teoblasts. Osteocalcin has 49 amino acids and is one of the 
most abundant non-collagen proteins in bone. The osteo-
calcin protein has three residues of the amino acid gamma-
carboxyglutamine acid, on position 17, 21 and 24. Gama-
carboxylation is vitamin K dependent and facilitates the 
binding of osteocalcin to hydroxyapatite in bone (12, 13). 
Vitamin D and parathyroid hormone are two major hor-
mones involved in osteocalcin production – PTH through 
binding to the receptor PTH1R and vitamin D through a 
vitamin D responsive element located in the promoter re-
gion of BGLAP gene. There is no data that there are osteo-
calcin receptors. It seems that osteocalcin modulates the 
activities of the G-coupled (GPRC6A) protein receptor. A 
carboxylated form of osteocalcin is involved in the regula-
tion of bone mineralization and is the modulator of bone 
cells, i.e. osteoblast and osteoclast activities (14). On the 
other hand, an uncarboxylated form of osteocalcin 
(unOC), is estimated to account for 50% of osteocalcin in 
the blood. Recent studies have demonstrated that the un-
carboxylated form of osteocalcin is involved in energy and 
glucose metabolism (15). Experimental and clinical data 
represent unOC as a novel endocrine stimulator of insulin 
and adiponectin secretion. Recent studies report a positive 
feedback loop by which insulin via insulin receptors on 
bone cells, i.e. osteoblasts increase the decarboxylation of 
osteocalcin. The result is an increased blood level of unOC, 
which increases insulin sensitivity and insulin secretion 
(16). A few studies reported a positive correlation between 
higher blood osteocalcin level and lower fasting plasma 
Figure 1. Synthesis of biomechanics (C, clinic).
Figure 2. Relationship between biomechanics and other scientific fields.
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glucose levels and better glycemic control (17,18). More 
experimental and clinical studies are need to confirm os-
teocalcin as an important factor in the reduction of insulin 
resistance, which, in turn, could prevent cardiovascular 
morbidity and mortality.
FGF 23
Fibroblast growth factor 23 (FGF 23) is a bone-derived 
hormone that regulates phosphate and vitamin D, 1, 25 
hydroxyvitamin D metabolism. FGF 23 is a 251 amino 
acid protein, molecular weight 26 kDa. It was found to 
be synthesized and secreted by osteoblast, but recent stud-
ies have shown that osteocytes are more important in the 
synthesis and secretion of FGF 23 (19). At the beginning 
of this century, FGF 23 was recognized as a gene respon-
sible for autosomal dominant hypoposphatemic rickets 
and a humoral factor responsible for tumor-induced os-
teomalacia. Today, the effect of FGF 23 on phosphate and 
vitamin D metabolism is well known. FGF 23 binds to 
receptors, FGFR1 receptors in the parathyroid cells and 
in distal convoluted tubule in the kidney. A cofactor, a- 
klotho, is needed for FGF 23 to bind to receptors. FGF 
23 increases urinary fraction excretion of phosphorus by 
reducing the expression of sodium phosphorus cotrans-
porter type II (NaPI II) and by suppressing 1 a-hydrox-
ylase activity (20). Moreover, FGF 23 also enhances 
24-hydroxylase activity, the effect of which is a decreased 
vitamin D level. Although the effect of FGF 23 on target 
organs, the kidneys (increased excretion of phosphorus, 
reduced synthesis and degradation of vitamin D) and 
parathyroid glands (reduced synthesis of parathyroid hor-
mone), is well known, the regulatory mechanism of FGF 
23 production is not sufficiently clear (10). There is no 
doubt that the phosphate level has some effect. Of interest 
are the findings that a high phosphate diet increases FGF 
23 levels, but acute changes of serum phosphate do not 
alter it (19). Vitamin D increases the level of FGF 23. In 
addition to the effect on phosphate, vitamin D and PTH 
levels, there are reports indicating the role of FGF 23 
level on blood vessel and heart. High FGF 23 levels are 
associated with the progression of left ventricular hyper-
trophy and aortic calcification, i.e. increased cardiovascu-
lar morbidity and mortality. This effect is probably indi-
rect because there are no a-klotho coreceptors in blood 
vessels and the heart (20, 21, 22).
There is no doubt that osteocalcin and FGF 23 are 
hormones secreted by bone cells. In addition to its other 
important functions, bone is also an important endocrine 
organ.
Bone material is able to grow together with the organ-
ism by constantly rebuilding and remodeling its structure. 
From a rheological point of view bone material flows 
through the bones and skeleton. Skeletal diseases, such as 
osteoporosis, are usually manifested by mechanical failure, 
or bone fracture, most often as Colles’ or hip fractures.
Experimental studies of the mechanical properties of 
bone are practically important in traumatological and 
orthopedic practice, particularly in investigations of bone 
fracture mechanisms and fracture healing.
Knowledge of the mechanical properties can predict the 
amount of load that a bone can bear and the amount of 
energy bone can absorb before fracturing. Material proper-
ties of substituted material, such as osteosynthetic or alo-
plastic devices, must be compatible with those of bones.
The geometry of bone, especially bone cross-section, is 
also an important biomechanical parameter and the best 
measure of the functional capacity of the skeleton related 
to its ability to sustain loads. The correlation coefficients 
between cross-sectional moments of inertia measured in 
vivo by non-invasive methods and calculated one and in 
vitro tested bending strength on isolated long bones is 
about 0,90 (23). One of the many problems of bone bio-
mechanics is the relationship of mechanics and the mate-
rial and geometrical properties of bone and aloplastic 
materials, such as osteosynthetic or prosthetic materials.
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